Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H34AuO9PS |
| Molecular Weight | 678.484 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[P](CC)(CC)[Au+][S-][C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
InChI
InChIKey=IRPYFWIZKIOHQN-XTZHGVARSA-N
InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/t10-,11-,12+,13-,14+;;/m1../s1
Auranofin (brand name Ridaura) is an organogold compound classified by the World Health Organization as an antirheumatic agent. Ridaura is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. The mechanism of action of is not understood. In patients with adult rheumatoid arthritis, it may modify disease activity as manifested by synovitis and associated symptoms, and reflected by laboratory parameters such as ESR. There is no substantial evidence, however, that gold-containing compounds induce remission of rheumatoid arthritis. It may act as an inhibitor of kappab kinase and thioredoxin reductase, which would lead to a decreased immune response and decreased free radical production, respectively. In patients with inflammatory arthritis, such as adult and juvenile rheumatoid arthritis, gold salts can decrease the inflammation of the joint lining. This effect can prevent destruction of bone and cartilage. Ridaura should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1991 |
|||
Target ID: P30044|||Q9UJU4 Gene ID: 25824.0 Gene Symbol: PRDX5 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | RIDAURA Approved UseRIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months. When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage. In controlled clinical trials comparing RIDAURA with injectable gold, RIDAURA was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of RIDAURA in patients who are candidates for chrysotherapy. Launch Date1985 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.312 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27821451 |
6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AURANOFIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.05 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27821451 |
6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AURANOFIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
844 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27821451 |
6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AURANOFIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.1310 |
unhealthy, 22-76 n = 72 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 22-76 Sex: M+F Population Size: 72 Sources: Page: p.1310 |
Disc. AE: Stomatitis, Diarrhea... AEs leading to discontinuation/dose reduction: Stomatitis (1.4%) Sources: Page: p.1310Diarrhea (1.4%) Eosinophilia (1.4%) Leukopenia (1.4%) |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.2 |
healthy, 27+/-5 n = 15 Health Status: healthy Age Group: 27+/-5 Sex: M+F Population Size: 15 Sources: Page: p.2 |
|
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
Disc. AE: Exanthema, Pruritus... AEs leading to discontinuation/dose reduction: Exanthema (7.5%) Sources: Page: p.254Pruritus (6%) Diarrhea (3%) Nausea (1.5%) Bowel obstruction (1.5%) Glomerulonephritis (1.5%) Nephropathies (1.5%) Polyneuropathy (1.5%) Sweating (1.5%) Dry mouth (1.5%) |
27 mg 1 times / day multiple, oral (total daily dose) Overdose Dose: 27 mg, 1 times / day Route: oral Route: multiple Dose: 27 mg, 1 times / day Sources: |
unhealthy, 50 n = 1 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 50 Sex: F Population Size: 1 Sources: |
Disc. AE: Encephalopathy, Peripheral neuropathy... AEs leading to discontinuation/dose reduction: Encephalopathy Sources: Peripheral neuropathy |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.266 |
unhealthy, 51 n = 115 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 51 Sex: M+F Population Size: 115 Sources: Page: p.266 |
Disc. AE: Distress gastrointestinal, Diarrhea... AEs leading to discontinuation/dose reduction: Distress gastrointestinal (0.9%) Sources: Page: p.266Diarrhea (3.5%) Rash (3.5%) Mucosal ulceration (2.6%) Leukopenia (0.9%) Proteinuria (2.6%) |
3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
Disc. AE: Hemoglobin decreased, Leukopenia... AEs leading to discontinuation/dose reduction: Hemoglobin decreased Sources: Leukopenia Agranulocytosis Thrombocytopenia Proteinuria Hematuria Pruritus Rash Stomatitis Diarrhea |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Diarrhea | 1.4% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.1310 |
unhealthy, 22-76 n = 72 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 22-76 Sex: M+F Population Size: 72 Sources: Page: p.1310 |
| Eosinophilia | 1.4% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.1310 |
unhealthy, 22-76 n = 72 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 22-76 Sex: M+F Population Size: 72 Sources: Page: p.1310 |
| Leukopenia | 1.4% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.1310 |
unhealthy, 22-76 n = 72 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 22-76 Sex: M+F Population Size: 72 Sources: Page: p.1310 |
| Stomatitis | 1.4% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.1310 |
unhealthy, 22-76 n = 72 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 22-76 Sex: M+F Population Size: 72 Sources: Page: p.1310 |
| Bowel obstruction | 1.5% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Dry mouth | 1.5% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Glomerulonephritis | 1.5% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Nausea | 1.5% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Nephropathies | 1.5% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Polyneuropathy | 1.5% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Sweating | 1.5% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Diarrhea | 3% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Pruritus | 6% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Exanthema | 7.5% Disc. AE |
6 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: Page: p.254 |
unhealthy, 45-63 n = 67 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 45-63 Sex: M+F Population Size: 67 Sources: Page: p.254 |
| Encephalopathy | Disc. AE | 27 mg 1 times / day multiple, oral (total daily dose) Overdose Dose: 27 mg, 1 times / day Route: oral Route: multiple Dose: 27 mg, 1 times / day Sources: |
unhealthy, 50 n = 1 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 50 Sex: F Population Size: 1 Sources: |
| Peripheral neuropathy | Disc. AE | 27 mg 1 times / day multiple, oral (total daily dose) Overdose Dose: 27 mg, 1 times / day Route: oral Route: multiple Dose: 27 mg, 1 times / day Sources: |
unhealthy, 50 n = 1 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 50 Sex: F Population Size: 1 Sources: |
| Distress gastrointestinal | 0.9% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.266 |
unhealthy, 51 n = 115 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 51 Sex: M+F Population Size: 115 Sources: Page: p.266 |
| Leukopenia | 0.9% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.266 |
unhealthy, 51 n = 115 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 51 Sex: M+F Population Size: 115 Sources: Page: p.266 |
| Mucosal ulceration | 2.6% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.266 |
unhealthy, 51 n = 115 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 51 Sex: M+F Population Size: 115 Sources: Page: p.266 |
| Proteinuria | 2.6% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.266 |
unhealthy, 51 n = 115 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 51 Sex: M+F Population Size: 115 Sources: Page: p.266 |
| Diarrhea | 3.5% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.266 |
unhealthy, 51 n = 115 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 51 Sex: M+F Population Size: 115 Sources: Page: p.266 |
| Rash | 3.5% Disc. AE |
3 mg 2 times / day multiple, oral Recommended Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: Page: p.266 |
unhealthy, 51 n = 115 Health Status: unhealthy Condition: Rheumatoid arthritis Age Group: 51 Sex: M+F Population Size: 115 Sources: Page: p.266 |
| Agranulocytosis | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Diarrhea | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Hematuria | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Hemoglobin decreased | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Leukopenia | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Proteinuria | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Pruritus | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Rash | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Stomatitis | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
| Thrombocytopenia | Disc. AE | 3 mg 3 times / day multiple, oral Recommended Dose: 3 mg, 3 times / day Route: oral Route: multiple Dose: 3 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Rheumatoid arthritis Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The subacute and chronic toxicity of SK&F 36914 and SK&F D-39162 in dogs. | 1978 Aug |
|
| [Multicenter double-blind comparison of auranofin and Tauredon]. | 1984 |
|
| Proteinuria in gold-treated rheumatoid arthritis. | 1984 Aug |
|
| Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria. | 1984 Jun |
|
| Neurotoxicity following a very high dose of oral gold (auranofin). | 1984 Nov |
|
| An analysis of worldwide safety experience with auranofin. | 1985 Aug |
|
| Long-term efficacy and safety of auranofin: a review of clinical experience. | 1986 |
|
| Auranofin versus penicillamine in rheumatoid arthritis. One-year results from a prospective clinical investigation. | 1986 |
|
| Nephrotic syndrome after oral gold. | 1986 Aug |
|
| Hematuria in patients with rheumatoid arthritis receiving gold and D-penicillamine. | 1987 Feb |
|
| [Gold-induced severe cholestatic jaundice in rheumatoid arthritis patient and effect of repeated steroid pulse therapy]. | 1992 Oct |
|
| Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes. | 1999 Nov 26 |
|
| HLA-DRB1*0301 and DQA1*0501 in RA. | 2001 Jul |
|
| Nitritoid reactions: case reports, review, and recommendations for management. | 2001 Oct |
|
| Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. | 2004 Oct |
|
| Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. | 2006 Dec 1 |
|
| A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]- to human serum albumin. | 2006 Jul |
|
| The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. | 2008 Oct 30 |
|
| Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. | 2011 Apr 14 |
|
| The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. | 2011 Feb |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
| Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells. | 2011 Jun |
|
| Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1. | 2011 Oct |
|
| Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. | 2011 Oct 1 |
|
| Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. | 2013 Oct |
Patents
Sample Use Guides
The usual adult dosage is 6 mg daily, given either as 3 mg twice daily or 6 mg once daily. Initiation of therapy at dosages exceeding 6 mg daily is not recommended because it is associated with an increased incidence of diarrhea. If response is inadequate after six months, an increase to 9 mg (3 mg three times daily) may be tolerated.
Route of Administration:
Oral
Auranofin possesses potent antibacterial activity against all tested strains of S. aureus, including meticillin-resistant S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA), with minimum inhibitory concentrations (MICs) ranging from 0.0625μg/mL to 0.125μg/mL.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
M01CB03
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
||
|
WHO-VATC |
QM01CB03
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
||
|
FDA ORPHAN DRUG |
305210
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
||
|
NCI_THESAURUS |
C574
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
||
|
LIVERTOX |
76
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID4020115
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
251-801-9
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL1366
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
SUB05610MIG
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
6918453
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
321521
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
6306
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
3H04W2810V
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
34031-32-8
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
C65242
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
D001310
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
3H04W2810V
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
100000086659
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
1227
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB00995
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
4122
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
m2139
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
Auranofin
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
2922
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
3972
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
7172
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY | |||
|
AURANOFIN
Created by
admin on Fri Dec 15 15:34:10 GMT 2023 , Edited by admin on Fri Dec 15 15:34:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
